NR4A1 and breast neoplasm: Although the proliferative and metastatic capacity of FAS is well-recognized [36], prior studies have similarly identified FAS overexpression in hormone receptor-positive and low-grade breast tumors [68, 69], suggesting that it may be important to consider other tumor characteristics when assessing the role of FAS in breast carcinogenesis.